The Suppressive Tumor Microenvironment: a Challenge in Cancer Immunotherapy

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2011 May 7

PMID 21545153

Citations 73

Authors

Elizabeth A Vasievich

Leaf Huang

Affiliations

Soon will be listed here.

Abstract

In this review, we introduce the changing public perception of vaccines and immunotherapy in cancer treatments. We discuss the roles that different immunosuppressive cells play in the tumor microenvironment. Tumor associated macrophages (TAMs) and M1 and M2 macrophage phenotypes are discussed in depth. Additionally, the role that myeloid derived suppressor cells (MDSC) and T regulatory cells (Tregs) play in the tumor microenvironment is addressed. Highlighted are examples of therapies used against each suppressive cell type, which vary from the hypothetical to the ineffective; the inefficient to the successful. A variety of treatments have been tried to combat this fundamental problem, indeed the cause that allows cancerous mutated cells to survive, multiply and overtake the body. Efficient methods to disable each particular suppressive type of cell have been introduced; this review summarizes the discussion with a table to guide future development. We see gene therapy as the most innovative and flexible method to lead the charge to specifically modifying the tumor microenvironment.

Citing Articles

Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review.

Tian Z, Hu R, Wang Z, Wang Y, Li W Arch Toxicol. 2024; 99(2):541-561.

PMID: 39729114 DOI: 10.1007/s00204-024-03941-w.

Multi-Epitopic Peptide Vaccine Against Newcastle Disease Virus: Molecular Dynamics Simulation and Experimental Validation.

Zeb M, Dumont E, Khan M, Shehzadi A, Ahmad I Vaccines (Basel). 2024; 12(11).

PMID: 39591153 PMC: 11598688. DOI: 10.3390/vaccines12111250.

The combination of apatinib and antigen-specific DC-induced T cells exert antitumor effects by potently improving the immune microenvironment of osteosarcoma.

Hu T, Sun W, Jin Y, Dong Y, Liu W, Sun Z Heliyon. 2024; 10(16):e36016.

PMID: 39224314 PMC: 11367533. DOI: 10.1016/j.heliyon.2024.e36016.

Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor-Associated Macrophages to Potentiate Cancer Immunotherapy.

Zhang C, Li J, Xu D, Wang D, Qi M, Chen F Adv Sci (Weinh). 2024; 11(38):e2403044.

PMID: 39119940 PMC: 11481252. DOI: 10.1002/advs.202403044.

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma.

Xing Z, Li X, He Z, Fang X, Liang H, Kuang C Pharmaceutics. 2024; 16(7).

PMID: 39065567 PMC: 11279595. DOI: 10.3390/pharmaceutics16070870.

References

Goforth R, Salem A, Zhu X, Miles S, Zhang X, Lee J . Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother. 2008; 58(4):517-30. PMC: 11030463. DOI: 10.1007/s00262-008-0574-6. View

Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T . FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007; 13(3):902-11. DOI: 10.1158/1078-0432.CCR-06-2363. View

Loberg R, Ying C, Craig M, Yan L, Snyder L, Pienta K . CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007; 9(7):556-62. PMC: 1939930. DOI: 10.1593/neo.07307. View

Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M . Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol. 2010; 185(11):6734-40. DOI: 10.4049/jimmunol.1000225. View

Lin W, Hsieh S . Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol. 2011; 81(7):838-47. DOI: 10.1016/j.bcp.2011.01.011. View

Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P . Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis. 2007; 24(2):121-30. DOI: 10.1007/s10585-007-9060-3. View

Levings M, Roncarolo M . T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol. 2000; 106(1 Pt 2):S109-12. DOI: 10.1067/mai.2000.106635. View

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

Rasku M, Clem A, Telang S, Taft B, Gettings K, Gragg H . Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008; 6:12. PMC: 2330026. DOI: 10.1186/1479-5876-6-12. View

10.

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A . Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008; 111(8):4233-44. DOI: 10.1182/blood-2007-07-099226. View

11.

Yang L, Huang J, Ren X, Gorska A, Chytil A, Aakre M . Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008; 13(1):23-35. PMC: 2245859. DOI: 10.1016/j.ccr.2007.12.004. View

12.

Kim H, Park H, Park J, Sohn H, Kim S, Kim H . Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine. 2010; 28(49):7787-96. DOI: 10.1016/j.vaccine.2010.09.046. View

13.

Kross K, Heimdal J, Olsnes C, Olofson J, Aarstad H . Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue. Acta Otolaryngol. 2007; 127(5):532-9. DOI: 10.1080/00016480600951384. View

14.

Habibi M, Kmieciak M, Graham L, Morales J, Bear H, Manjili M . Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Res Treat. 2008; 114(3):423-31. PMC: 2649692. DOI: 10.1007/s10549-008-0024-3. View

15.

Matsushita N, Pilon-Thomas S, Martin L, Riker A . Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods. 2008; 333(1-2):167-79. PMC: 2577585. DOI: 10.1016/j.jim.2008.01.012. View

16.

Luo Y, Zhou H, Krueger J, Kaplan C, Lee S, Dolman C . Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006; 116(8):2132-2141. PMC: 1513049. DOI: 10.1172/JCI27648. View

17.

Woo E, Chu C, Goletz T, Schlienger K, Yeh H, Coukos G . Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61(12):4766-72. View

18.

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View

19.

Suzuki E, Kapoor V, Jassar A, Kaiser L, Albelda S . Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005; 11(18):6713-21. DOI: 10.1158/1078-0432.CCR-05-0883. View

20.

Zijlmans H, Fleuren G, Baelde H, Eilers P, Kenter G, Gorter A . The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol. 2006; 208(4):507-17. DOI: 10.1002/path.1918. View